Hemophagocytosis during fludarabine-based SCT for systemic juvenile idiopathic arthritis [1]

Bone Marrow Transplantation

Volumn 38, Issue 3, 2006, Pages 249-251

  Ferreira, R A ^a,b   Vastert, S J ^a   Abinun, M ^c   Foster, H E ^c   Modesto, C ^d   Olive T ^d   Kuis, W ^a   Wulffraat, N M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^d HOSPITAL MATERNO INFANTIL VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; FOSCARNET; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE; PREDNISOLONE; THYMOCYTE ANTIBODY; VALACICLOVIR;

ABDOMINAL PAIN; ADOLESCENT; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CASE REPORT; CYTOMEGALOVIRUS; DOSE RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROPHAGOCYTOSIS; FEMALE; FEVER; FOLLOW UP; HEPATOMEGALY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LETHARGY; LETTER; MACROPHAGE ACTIVATION; MACROPHAGE ACTIVATION SYNDROME; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; REMISSION; RETICULOENDOTHELIOSIS; RISK REDUCTION; SCHOOL CHILD; STEM CELL MOBILIZATION; TACHYPNEA; VIRUS REACTIVATION;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; HUMANS; MACROPHAGE ACTIVATION; MALE; MYELOABLATIVE AGONISTS; STEM CELL TRANSPLANTATION; SYNDROME; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; VIDARABINE;

EID: 33746355619     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705415     Document Type: Letter

References (10)

1. Wulffraat N, van Royen A, Bierings M, Vossen J, Kuis W. Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet 1999; 353: 550-553.
2. De Kleer IM, Brinkman DM, Ferster A, Abinun M, Quartier P, Van Der NJ et al. Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: Analysis of clinical effects, mortality, and transplant related morbidity. Ann Rheum Dis 2004; 63: 1318-1326.
3. Janka G, Zur SU. Familial and acquired hemophagocytic lymphohistiocytosis. Hematology (Am Soc Hematol Educ Program) 2005; 82-8: 82-88.
4. Grom AA, Villanueva J, Lee S, Goldmuntz EA, Passo MH, Filipovich A. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr 2003; 142: 292-296.
5. Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 2005; 7: R30-R37.
6. Aboulafia DM, Demirer T. Fatal bone marrow necrosis following fludarabine administration in a patient with indolent lymphoma. Leuk Lymphoma 1995; 19: 181-184.
7. Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. Int J Hematol 1997; 66: 135-151.
8. Hertzberger-ten Cate R, Cats A. Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 85-88.
9. Ravelli A, Caria MC, Buratti S, Malattia C, Temporini F, Martini A. Methotrexate as a possible trigger of macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol 2001; 28: 865-867.
10. Ramanan AV, Grom AA. Does systemic-onset juvenile idiopathic arthritis belong under juvenile idiopathic arthritis? Rheumatology (Oxford) 2005; 44: 1350-1353.